1|Page
CALIFORNIA CHEMICAL DEPENDENCY
COUNSELOR Final Exam Newest Exam Preparation
With Complete Questions And Correct Answers With
Rationales | Already Graded A+||Brand New Version!!
QUESTION 1
A 45-year-old client with a 20-year history of alcohol use disorder
presents for intake. He reports drinking a fifth of whiskey daily. His last
drink was approximately 18 hours ago. He is tachycardic, hypertensive,
diaphoretic, and reports visual hallucinations of insects crawling on the
walls. Which of the following best describes the client's current clinical
status?
A) Alcoholic hallucinosis
B) Uncomplicated alcohol withdrawal
C) Delirium tremens
D) Wernicke-Korsakoff syndrome
ANSWER: C) Delirium tremens
EXPLANATION: Delirium tremens (DTs) represents the most severe form
of alcohol withdrawal, typically occurring 48-96 hours after the last
,2|Page
drink but can present earlier in some cases. The classic triad includes
autonomic hyperactivity (tachycardia, hypertension, diaphoresis), global
confusional state, and visual/tactile hallucinations. This client presents
with all three components. Alcoholic hallucinosis (A) involves
hallucinations in a clear sensorium without autonomic dysfunction.
Uncomplicated withdrawal (B) may include mild autonomic symptoms
but not hallucinations or severe confusion. Wernicke-Korsakoff
syndrome (D) is characterized by ophthalmoplegia, ataxia, and
confusion related to thiamine deficiency, not acute withdrawal
symptoms.
QUESTION 2
According to the American Society of Addiction Medicine (ASAM)
criteria, which of the following dimensions is NOT assessed during a
multidimensional patient assessment?
A) Acute intoxication and/or withdrawal potential
B) Biomedical conditions and complications
C) Employment and vocational functioning
D) Recovery environment and support systems
ANSWER: C) Employment and vocational functioning
EXPLANATION: The ASAM Six Dimensions include: Dimension 1 (Acute
intoxication/withdrawal), Dimension 2 (Biomedical conditions),
Dimension 3 (Emotional/behavioral/cognitive conditions), Dimension 4
(Readiness to change), Dimension 5 (Relapse/continued use potential),
,3|Page
and Dimension 6 (Recovery environment). While employment is a
relevant consideration in treatment planning, it is not one of the six
formal ASAM assessment dimensions. The dimensions are specifically
designed to evaluate risk and determine appropriate level of care
placement across the continuum of addiction treatment services.
QUESTION 3
A counselor is working with a client who reports that she only drinks
wine on weekends and that she "can stop anytime." She has been
arrested twice for DUI in the past three years and her employer has
placed her on probation due to attendance issues. Which defense
mechanism is the client most likely employing?
A) Projection
B) Rationalization
C) Denial
D) Intellectualization
ANSWER: C) Denial
EXPLANATION: Denial is the refusal to acknowledge the reality of a
situation or the severity of one's problems. This client minimizes her
drinking by stating she "only drinks on weekends" and claims she can
stop anytime, despite objective evidence to the contrary including DUIs
and employment consequences. Denial operates at a preconscious level
and is considered a primitive defense mechanism. Rationalization (B)
involves creating logical-sounding explanations for behavior, while
, 4|Page
projection (A) involves attributing one's own feelings to others.
Intellectualization (D) involves using abstract thinking to avoid
emotional impact. The client's statements represent a classic
presentation of denial in substance use disorders.
QUESTION 4
Which of the following medications is FDA-approved for the treatment
of opioid use disorder and functions as a partial mu-opioid receptor
agonist?
A) Methadone
B) Buprenorphine
C) Naltrexone
D) Naloxone
ANSWER: B) Buprenorphine
EXPLANATION: Buprenorphine is a partial agonist at the mu-opioid
receptor, meaning it produces a ceiling effect for respiratory depression
and has lower abuse potential than full agonists. It is FDA-approved for
opioid use disorder treatment and can be prescribed in office-based
settings by qualified physicians. Methadone (A) is a full mu-opioid
agonist requiring specialized clinics for dispensing. Naltrexone (C) is an
opioid antagonist that blocks opioid receptors without activating them.
Naloxone (D) is a short-acting opioid antagonist used primarily for
overdose reversal, not maintenance treatment.
CALIFORNIA CHEMICAL DEPENDENCY
COUNSELOR Final Exam Newest Exam Preparation
With Complete Questions And Correct Answers With
Rationales | Already Graded A+||Brand New Version!!
QUESTION 1
A 45-year-old client with a 20-year history of alcohol use disorder
presents for intake. He reports drinking a fifth of whiskey daily. His last
drink was approximately 18 hours ago. He is tachycardic, hypertensive,
diaphoretic, and reports visual hallucinations of insects crawling on the
walls. Which of the following best describes the client's current clinical
status?
A) Alcoholic hallucinosis
B) Uncomplicated alcohol withdrawal
C) Delirium tremens
D) Wernicke-Korsakoff syndrome
ANSWER: C) Delirium tremens
EXPLANATION: Delirium tremens (DTs) represents the most severe form
of alcohol withdrawal, typically occurring 48-96 hours after the last
,2|Page
drink but can present earlier in some cases. The classic triad includes
autonomic hyperactivity (tachycardia, hypertension, diaphoresis), global
confusional state, and visual/tactile hallucinations. This client presents
with all three components. Alcoholic hallucinosis (A) involves
hallucinations in a clear sensorium without autonomic dysfunction.
Uncomplicated withdrawal (B) may include mild autonomic symptoms
but not hallucinations or severe confusion. Wernicke-Korsakoff
syndrome (D) is characterized by ophthalmoplegia, ataxia, and
confusion related to thiamine deficiency, not acute withdrawal
symptoms.
QUESTION 2
According to the American Society of Addiction Medicine (ASAM)
criteria, which of the following dimensions is NOT assessed during a
multidimensional patient assessment?
A) Acute intoxication and/or withdrawal potential
B) Biomedical conditions and complications
C) Employment and vocational functioning
D) Recovery environment and support systems
ANSWER: C) Employment and vocational functioning
EXPLANATION: The ASAM Six Dimensions include: Dimension 1 (Acute
intoxication/withdrawal), Dimension 2 (Biomedical conditions),
Dimension 3 (Emotional/behavioral/cognitive conditions), Dimension 4
(Readiness to change), Dimension 5 (Relapse/continued use potential),
,3|Page
and Dimension 6 (Recovery environment). While employment is a
relevant consideration in treatment planning, it is not one of the six
formal ASAM assessment dimensions. The dimensions are specifically
designed to evaluate risk and determine appropriate level of care
placement across the continuum of addiction treatment services.
QUESTION 3
A counselor is working with a client who reports that she only drinks
wine on weekends and that she "can stop anytime." She has been
arrested twice for DUI in the past three years and her employer has
placed her on probation due to attendance issues. Which defense
mechanism is the client most likely employing?
A) Projection
B) Rationalization
C) Denial
D) Intellectualization
ANSWER: C) Denial
EXPLANATION: Denial is the refusal to acknowledge the reality of a
situation or the severity of one's problems. This client minimizes her
drinking by stating she "only drinks on weekends" and claims she can
stop anytime, despite objective evidence to the contrary including DUIs
and employment consequences. Denial operates at a preconscious level
and is considered a primitive defense mechanism. Rationalization (B)
involves creating logical-sounding explanations for behavior, while
, 4|Page
projection (A) involves attributing one's own feelings to others.
Intellectualization (D) involves using abstract thinking to avoid
emotional impact. The client's statements represent a classic
presentation of denial in substance use disorders.
QUESTION 4
Which of the following medications is FDA-approved for the treatment
of opioid use disorder and functions as a partial mu-opioid receptor
agonist?
A) Methadone
B) Buprenorphine
C) Naltrexone
D) Naloxone
ANSWER: B) Buprenorphine
EXPLANATION: Buprenorphine is a partial agonist at the mu-opioid
receptor, meaning it produces a ceiling effect for respiratory depression
and has lower abuse potential than full agonists. It is FDA-approved for
opioid use disorder treatment and can be prescribed in office-based
settings by qualified physicians. Methadone (A) is a full mu-opioid
agonist requiring specialized clinics for dispensing. Naltrexone (C) is an
opioid antagonist that blocks opioid receptors without activating them.
Naloxone (D) is a short-acting opioid antagonist used primarily for
overdose reversal, not maintenance treatment.
